Vanguard Group Inc. Raises Stock Position in Kymera Therapeutics, Inc. $KYMR

Key Points

• Vanguard Group Inc. has increased its stake in Kymera Therapeutics by 7.0%, holding approximately 8.03% of the company, valued at $143.18 million.
• Kymera Therapeutics reported a quarterly loss of ($0.95) EPS, missing analyst estimates, with revenue down 55.1% year-on-year.
• Analysts have set a consensus target price of $59.11 for Kymera Therapeutics, with several firms rating the stock as a "Buy" or "Strong Buy."

Vanguard Group Inc. grew its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 7.0% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,231,392 shares of the company's stock after buying an additional 344,080 shares during the quarter. Vanguard Group Inc. owned approximately 8.03% of Kymera Therapeutics worth $143,183,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of KYMR. State of Wyoming bought a new stake in shares of Kymera Therapeutics during the fourth quarter worth $45,000. GF Fund Management CO. LTD. bought a new stake in shares of Kymera Therapeutics during the fourth quarter worth $55,000. KBC Group NV grew its stake in shares of Kymera Therapeutics by 15.2% during the first quarter. KBC Group NV now owns 2,479 shares of the company's stock worth $68,000 after buying an additional 328 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Kymera Therapeutics by 3,851.5% in the first quarter. GAMMA Investing LLC now owns 6,678 shares of the company's stock worth $183,000 after purchasing an additional 6,509 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Kymera Therapeutics by 95.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,812 shares of the company's stock worth $194,000 after purchasing an additional 2,350 shares during the last quarter.

Insider Buying and Selling

In related news, CEO Nello Mainolfi sold 30,000 shares of the company's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total transaction of $1,470,000.00. Following the completion of the sale, the chief executive officer owned 660,482 shares in the company, valued at approximately $32,363,618. This represents a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey W. Albers sold 6,349 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $311,101.00. The disclosure for this sale can be found here. Insiders have sold 48,349 shares of company stock worth $2,334,301 over the last 90 days. Insiders own 16.01% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Bank of America raised shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price objective on the stock in a research note on Monday, June 2nd. B. Riley upgraded shares of Kymera Therapeutics to a "strong-buy" rating and set a $60.00 target price on the stock in a report on Wednesday, July 30th. UBS Group lowered their target price on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. The Goldman Sachs Group upgraded shares of Kymera Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 15th. Finally, Guggenheim restated a "buy" rating and set a $60.00 price target on shares of Kymera Therapeutics in a research note on Tuesday, June 3rd. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Kymera Therapeutics currently has an average rating of "Buy" and a consensus target price of $59.11.

Kymera Therapeutics Price Performance

NASDAQ:KYMR traded down $1.3570 during trading hours on Monday, hitting $42.7430. The stock had a trading volume of 105,901 shares, compared to its average volume of 739,760. The company has a 50 day simple moving average of $44.17 and a two-hundred day simple moving average of $36.59. Kymera Therapeutics, Inc. has a one year low of $19.44 and a one year high of $53.27. The firm has a market capitalization of $3.06 billion, a price-to-earnings ratio of -12.31 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The company had revenue of $11.48 million for the quarter, compared to the consensus estimate of $17.37 million. During the same period in the prior year, the firm posted ($0.58) earnings per share. The business's revenue was down 55.1% on a year-over-year basis. Equities research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.